1-3 of 3
Kyle A. Beckwith, PhD
Close
Sort by
Journal Articles

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma

Deborah M Stephens, DO, Kyle A. Beckwith, PhD, Priscilla Do, BS, Carolyn Cheney, BS, Xiaokui Mo, PhD MAS, Karilyn Larkin, MD, Jeffrey Jones, MD MPH, Farrukh T. Awan, Laura Grosmaire, PhD, Randy Jones, PhD, Julie DiPaolo, PhD, Stacey Tannheimer, Karl-Heinz Heider, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD
Journal: Blood
Blood (2016) 128 (22): 2767.
https://doi.org/10.1182/blood.V128.22.2767.2767
Published: 2016
Journal Articles

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Meixiao Long, MD PhD, Kyle A. Beckwith, PhD, Priscilla Do, BS, Mundy L Bethany, PhD, Gordon Gordon, Amy M. Lehman, MAS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Joseph A. Fraietta, PhD, Carl H June, MD, Marcela V. Maus, MDPhD, Jennifer A. Woyach, MD, Michael A. Caligiuri, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Journal: Blood
Blood (2016) 128 (22): 3238.
https://doi.org/10.1182/blood.V128.22.3238.3238
Published: 2016
Journal Articles

Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis

Priscilla Do, BS, Kyle A. Beckwith, PhD, Larry Beaver, Brittany G. Griffin, Xiaokui Mo, PhD MAS, Jeffrey Jones, MD MPH, Erin K. Hertlein, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Journal: Blood
Blood (2016) 128 (22): 3221.
https://doi.org/10.1182/blood.V128.22.3221.3221
Published: 2016